Project TitleBiomarkers for Diagnosis of Depression and PTSD
Track Code2010-062, 2013-167, 2013-168
Short Description

Novel blood test for accurately diagnosing depression and post-traumatic stress disorder

#diagnostics #marker #healthcare #diagnostictool #psychiatry #depression

Northwestern researchers have discovered a set of genes whose expression levels differ in the blood of animals that show either high or low levels of depressive behavior. Prof. Eva Redei and colleagues identified a set of genes differentially expressed in the blood of adolescents and adults with major depressive disorder (MDD) and biomarkers for post-traumatic stress disorder (PTSD), which can sometimes co-occur with depression. Currently, there are no biological diagnostic tools for depression and PTSD. In addition,  there are no predictive tools to help clinicians determine how a particular patient will respond to therapy. However, the discoveries of these sets of biomarkers could enable clinicians to rapidly and unequivocally diagnose patients and determine the optimal course of treatment. Introduction of these tests into the clinic may improve patient outcomes by reducing the risk of inaccurate diagnosis as well as facilitating management of at-risk populations.

TagsDIAGNOSTICS: marker, HEALTHCARE: Diagnostic Tool, PSYCHIATRY: depression
Posted DateFeb 19, 2013 4:51 PM


Eva Redei*
Brian Andrus


  • Diagnostic tools for MDD and PTSD
  • Identification of patients at risk for relapse
  • Prediction of treatment response


• First biological diagnostic for both depression and PTSD

• Improved management of at-risk patients 

• Reduced misclassification of behavior


IP Status

International and US patent applications have been filed.

Contact Information

Michael Moore, PhD
Invention Manager
(p) 847.491.4645